Comparison between intravitreal ranibizumab injection and posterior subtenon triamcinolone acetonide injection at time of cataract surgery for prevention of progression of diabetic macular edema
Abstract Background The goal of this work is to assess progression of diabetic macular edema (DME) following intravitreal ranibizumab injection compared to subtenon triamcinolone acetonide injection at cataract operation. Methods Retrospective analysis of 73 eyes of 65 participant with DME, with cen...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2022-12-01
|
| Series: | BMC Ophthalmology |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s12886-022-02625-2 |
| _version_ | 1811292030588944384 |
|---|---|
| author | Mahmoud Mohammed Ahmed Ali Khalil Hosam Othman Mansour Ahmed Mohamed Raafat Tawfik Ahmed Gomaa Elmahdy |
| author_facet | Mahmoud Mohammed Ahmed Ali Khalil Hosam Othman Mansour Ahmed Mohamed Raafat Tawfik Ahmed Gomaa Elmahdy |
| author_sort | Mahmoud Mohammed Ahmed Ali Khalil |
| collection | DOAJ |
| description | Abstract Background The goal of this work is to assess progression of diabetic macular edema (DME) following intravitreal ranibizumab injection compared to subtenon triamcinolone acetonide injection at cataract operation. Methods Retrospective analysis of 73 eyes of 65 participant with DME, with central macular thickness (CMT) ≥ 300 μm. The included eyes were separated into three groups; phacoemulsification with intravitreal Ranibizumab injection group, phacoemulsification with subtenon Triamcinolone acetonide injection group and phacoemulsification only group. Main measures involved best corrected visual acuity (BCVA) one week, one month and three months post-operative. The CMT was compared preoperative and postoperative (one and three months). Results After 1 month of operation, there was a statistical substantial distinction in the median of CMT between ranibizumab & control group (p < 0.001), between subtenon TA & control group (p < 0.001) and in ranibizumab and subtenon TA group (p = 0.023). After 3 months, the variance between ranibizumab & control group was considerable (p < 0.0001) and the variance between subtenon TA & control group was considerable (p = 0.030). Conclusions Combined phacoemulsification with intravitreal injections of ranibizumab or subtenon triamcinolone acetonide may prevent further progression in CMT in individuals with DME following cataract operation. |
| first_indexed | 2024-04-13T04:38:20Z |
| format | Article |
| id | doaj.art-f8b99e7e1c9a4fee8dd64d3a891a8c45 |
| institution | Directory Open Access Journal |
| issn | 1471-2415 |
| language | English |
| last_indexed | 2024-04-13T04:38:20Z |
| publishDate | 2022-12-01 |
| publisher | BMC |
| record_format | Article |
| series | BMC Ophthalmology |
| spelling | doaj.art-f8b99e7e1c9a4fee8dd64d3a891a8c452022-12-22T03:02:06ZengBMCBMC Ophthalmology1471-24152022-12-012211810.1186/s12886-022-02625-2Comparison between intravitreal ranibizumab injection and posterior subtenon triamcinolone acetonide injection at time of cataract surgery for prevention of progression of diabetic macular edemaMahmoud Mohammed Ahmed Ali Khalil0Hosam Othman Mansour1Ahmed Mohamed Raafat Tawfik2Ahmed Gomaa Elmahdy3Department of Ophthalmology, Al Azhar UniversityMagrabi Eye Hospital TantaDepartment of Ophthalmology, Al Azhar UniversityDepartment of Ophthalmology, Al Azhar UniversityAbstract Background The goal of this work is to assess progression of diabetic macular edema (DME) following intravitreal ranibizumab injection compared to subtenon triamcinolone acetonide injection at cataract operation. Methods Retrospective analysis of 73 eyes of 65 participant with DME, with central macular thickness (CMT) ≥ 300 μm. The included eyes were separated into three groups; phacoemulsification with intravitreal Ranibizumab injection group, phacoemulsification with subtenon Triamcinolone acetonide injection group and phacoemulsification only group. Main measures involved best corrected visual acuity (BCVA) one week, one month and three months post-operative. The CMT was compared preoperative and postoperative (one and three months). Results After 1 month of operation, there was a statistical substantial distinction in the median of CMT between ranibizumab & control group (p < 0.001), between subtenon TA & control group (p < 0.001) and in ranibizumab and subtenon TA group (p = 0.023). After 3 months, the variance between ranibizumab & control group was considerable (p < 0.0001) and the variance between subtenon TA & control group was considerable (p = 0.030). Conclusions Combined phacoemulsification with intravitreal injections of ranibizumab or subtenon triamcinolone acetonide may prevent further progression in CMT in individuals with DME following cataract operation.https://doi.org/10.1186/s12886-022-02625-2Subtenon Triamcinolone acetonideIntravitreal ranibizumabPhacoemulsificationDiabetic macular edema |
| spellingShingle | Mahmoud Mohammed Ahmed Ali Khalil Hosam Othman Mansour Ahmed Mohamed Raafat Tawfik Ahmed Gomaa Elmahdy Comparison between intravitreal ranibizumab injection and posterior subtenon triamcinolone acetonide injection at time of cataract surgery for prevention of progression of diabetic macular edema BMC Ophthalmology Subtenon Triamcinolone acetonide Intravitreal ranibizumab Phacoemulsification Diabetic macular edema |
| title | Comparison between intravitreal ranibizumab injection and posterior subtenon triamcinolone acetonide injection at time of cataract surgery for prevention of progression of diabetic macular edema |
| title_full | Comparison between intravitreal ranibizumab injection and posterior subtenon triamcinolone acetonide injection at time of cataract surgery for prevention of progression of diabetic macular edema |
| title_fullStr | Comparison between intravitreal ranibizumab injection and posterior subtenon triamcinolone acetonide injection at time of cataract surgery for prevention of progression of diabetic macular edema |
| title_full_unstemmed | Comparison between intravitreal ranibizumab injection and posterior subtenon triamcinolone acetonide injection at time of cataract surgery for prevention of progression of diabetic macular edema |
| title_short | Comparison between intravitreal ranibizumab injection and posterior subtenon triamcinolone acetonide injection at time of cataract surgery for prevention of progression of diabetic macular edema |
| title_sort | comparison between intravitreal ranibizumab injection and posterior subtenon triamcinolone acetonide injection at time of cataract surgery for prevention of progression of diabetic macular edema |
| topic | Subtenon Triamcinolone acetonide Intravitreal ranibizumab Phacoemulsification Diabetic macular edema |
| url | https://doi.org/10.1186/s12886-022-02625-2 |
| work_keys_str_mv | AT mahmoudmohammedahmedalikhalil comparisonbetweenintravitrealranibizumabinjectionandposteriorsubtenontriamcinoloneacetonideinjectionattimeofcataractsurgeryforpreventionofprogressionofdiabeticmacularedema AT hosamothmanmansour comparisonbetweenintravitrealranibizumabinjectionandposteriorsubtenontriamcinoloneacetonideinjectionattimeofcataractsurgeryforpreventionofprogressionofdiabeticmacularedema AT ahmedmohamedraafattawfik comparisonbetweenintravitrealranibizumabinjectionandposteriorsubtenontriamcinoloneacetonideinjectionattimeofcataractsurgeryforpreventionofprogressionofdiabeticmacularedema AT ahmedgomaaelmahdy comparisonbetweenintravitrealranibizumabinjectionandposteriorsubtenontriamcinoloneacetonideinjectionattimeofcataractsurgeryforpreventionofprogressionofdiabeticmacularedema |